Meropenem Venus (Meropenem)

Meropenem is a broad‑spectrum carbapenem used for serious infections that require intravenous therapy.

• Complicated intra‑abdominal infections: provides extensive coverage against Gram‑negative, Gram‑positive and anaerobic bacteria to achieve clinical cure.
• Complicated urinary tract infections: eradicates resistant uropathogens, facilitating resolution of infection.
• Hospital‑acquired pneumonia: delivers rapid bactericidal activity against typical and atypical respiratory pathogens.
• Ventilator‑associated pneumonia: penetrates lung tissue to treat ventilator‑related bacterial colonisation.
• Meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat central nervous system infections.
• Severe sepsis and septic shock: offers immediate broad‑spectrum activity to control systemic infection.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its resistance to most β‑lactamases allows activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient and usually resolves.
• Infusion site phlebitis: pain or redness at the catheter site.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile infection: severe colitis requiring prompt treatment.
• Anaphylaxis: acute hypersensitivity reaction with respiratory compromise.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: worsening kidney function in susceptible individuals.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Allergy assessment: avoid in individuals with known carbapenem hypersensitivity.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Concomitant nephrotoxic drugs: monitor renal parameters closely.
• Therapeutic drug monitoring: consider in critically ill patients with altered pharmacokinetics.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: increased risk of seizures when combined.
• Probenecid: may reduce renal clearance of meropenem, leading to higher plasma levels.
• Cytotoxic chemotherapy agents: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely)

• Loop diuretics: monitor renal function and electrolytes.
• Aminoglycosides: increased risk of nephrotoxicity; assess kidney markers.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters for potential changes.
• Oral contraceptives: reduced efficacy possible; advise alternative contraception.
• NSAIDs: watch for additive renal effects.